A Phase II Study of Bendamustine Plus Rituximab in Patients with Relapsed or Progressive Marginal Zone Lymphoma: KCSG LY14-09
Bendamustine plus rituximab is a highly effective and tolerable treatment for patients with relapsed or progressive MZL, providing durable disease control.
Authors
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0003-3924-0434)
- Ho‐Young Yhim (ORCID: https://orcid.org/0000-0002-1252-5336)
- Jeong-Ok Lee
- Dae Seog Heo (ORCID: https://orcid.org/0000-0001-5221-173X)
- Shin Young Hyun (ORCID: https://orcid.org/0000-0002-8137-8675)
- Gyeong‐Won Lee (ORCID: https://orcid.org/0000-0002-1781-2262)
- Jinny Park (ORCID: https://orcid.org/0009-0005-3186-3591)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Jong Seok Lee (ORCID: https://orcid.org/0000-0002-3892-3439)
- Hye Jin Kang
Institutions
- Gachon University (KR)
- Yonsei University (KR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- Korea Institute of Radiological and Medical Sciences (KR)
- Gyeongsang National University Hospital (KR)
- Hallym University Sacred Heart Hospital (KR)
- Jeonbuk National University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-12-03
- DOI
- https://doi.org/10.4143/crt.2025.815
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eisai
- Eisai Korea